Skip to main content

Advertisement

SpringerLink
Log in

Authors’ reply to Gandjour: “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”

  • Reply
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

The Original Article was published on 06 February 2018

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Gandjour, A.: Comment on “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”

  2. Kuhlmann, A., von der Schulenburg, J.-M.G.: Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. Eur. J. Health. Econ. 18(3), 273–292 (2017). https://doi.org/10.1007/s10198-016-0770-9

    Article  PubMed  Google Scholar 

  3. Tregnaghi, M.W., Sáez-Llorens, X., López, P., Abate, H., Smith, E., Pósleman, A., Calvo, A., Wong, D., Cortes-Barbosa, C., Ceballos, A., Tregnaghi, M., Sierra, A., Rodriguez, M., Troitiño, M., Carabajal, C., Falaschi, A., Leandro, A., Castrejón, M.M., Lepetic, A., Lommel, P., Hausdorff, W.P., Borys, D., Ruiz Guiñazú, J., Ortega-Barría, E., Yarzábal, J.P., Schuerman, L.: Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children. A double-blind randomized controlled trial. PLoS Med. 11(6), e1001657 (2014). https://doi.org/10.1371/journal.pmed.1001657

    Article  PubMed  PubMed Central  Google Scholar 

  4. Prymula, R., Peeters, P., Chrobok, V., Kriz, P., Novakova, E., Kaliskova, E., Kohl, I., Lommel, P., Poolman, J., Prieels, J.-P., Schuerman, L.: Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae. A randomised double-blind efficacy study. The Lancet 367(9512), 740–748 (2006). https://doi.org/10.1016/S0140-6736(06)68304-9

    Article  CAS  Google Scholar 

  5. von Kries, R., Toschke, A.M., Siedler, A.: Population-based nationwide study on invasive pneumococcal infections among children in Germany (1997–2003) (unpublished)

  6. van Hoek, A.J., Andrews, N., Waight, P.A., Stowe, J., Gates, P., George, R., Miller, E.: The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J. Infect. 65(1), 17–24 (2012). https://doi.org/10.1016/j.jinf.2012.02.017

    Article  PubMed  Google Scholar 

  7. Federal Statistical Office of Germany (Statistisches Bundesamt): Diagnosedaten der Krankenhäuser ab 2000 (2013)

  8. Melegaro, A., Edmunds, W.J.: Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 22(31–32), 4203–4214 (2004). https://doi.org/10.1016/j.vaccine.2004.05.003

    Article  CAS  PubMed  Google Scholar 

  9. Mangen, M.-J.J., Huijts, S.M., Bonten, M.J.M., de Wit, G.A.: The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect. Dis. 17(1), 208 (2017). https://doi.org/10.1186/s12879-017-2302-3

    Article  PubMed  PubMed Central  Google Scholar 

  10. Mangen, M.-J.J., Rozenbaum, M.H., Huijts, S.M., van Werkhoven, C.H., Postma, D.F., Atwood, M., van Deursen, A.M.M., van der Ende, A., Grobbee, D.E., Sanders, E.A.M., Sato, R., Verheij, T.J.M., Vissink, C.E., Bonten, M.J.M., de Wit, G.A.: Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur. Respir. J. 46(5), 1407–1416 (2015). https://doi.org/10.1183/13993003.00325-2015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Rozenbaum, M.H., Sanders, E.A.M., van Hoek, A.J., Jansen, A.G.S.C., van der Ende, A., van den Dobbelsteen, G., Rodenburg, G.D., Hak, E., Postma, M.J.: Cost effectiveness of pneumococcal vaccination among Dutch infants. Economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ (Clin. Res. Ed.) 340, 2509 (2010). https://doi.org/10.1136/bmj.c2509

    Article  Google Scholar 

  12. Garrison, L.P., Mansley, E.C., Abbott, T.A., Bresnahan, B.W., Hay, J.W., Smeeding, J.: Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR drug cost task force report—part II. Value Health 13(1), 8–13 (2010). https://doi.org/10.1111/j.1524-4733.2009.00660.x

    Article  PubMed  Google Scholar 

  13. Garber, A.M.: Chapter 4: advances in cost-effectiveness analysis of health interventions. In: Handbook of Health Economics, vol. 1. Elsevier, Amsterdam, pp. 181–221 (2000)

  14. Posner, R.A.: The social costs of monopoly and regulation. J. Political Econ. 83(4), 807–827 (1975)

    Article  Google Scholar 

  15. Black, S.B., Shinefield, H.R., Ling, S., Hansen, J., Fireman, B., Spring, D., Noyes, J., Lewis, E., Ray, P., Lee, J., Hackell, J.: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21(9), 810–815 (2002). https://doi.org/10.1097/01.inf.0000027926.99356.4c

    Article  PubMed  Google Scholar 

  16. Black, S., Shinefield, H., Fireman, B., Lewis, E., Ray, P., Hansen, J.R., Elvin, L., Ensor, K.M., Hackell, J., Siber, G., Malinoski, F., Madore, D., Chang, I., Kohberger, R., Watson, W., Austrian, R., Edwards, K.: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19(3), 187–195 (2000)

    Article  CAS  PubMed  Google Scholar 

  17. Palmu, A.A., Jokinen, J., Borys, D., Nieminen, H., Ruokokoski, E., Siira, L., Puumalainen, T., Lommel, P., Hezareh, M., Moreira, M., Schuerman, L., Kilpi, T.M.: Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease. A cluster randomised trial. The Lancet 381(9862), 214–222 (2013). https://doi.org/10.1016/S0140-6736(12)61854-6

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Health Economics Research Hannover (CHERH), Leibniz Universität Hannover, Otto-Brenner-Straße 1, 30159, Hanover, Germany

    Alexander Kuhlmann & J.-Matthias Graf von der Schulenburg

Authors
  1. Alexander Kuhlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J.-Matthias Graf von der Schulenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Kuhlmann.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kuhlmann, A., von der Schulenburg, JM.G. Authors’ reply to Gandjour: “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”. Eur J Health Econ 19, 473–481 (2018). https://doi.org/10.1007/s10198-018-0956-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-018-0956-4

Search

Navigation